Drug Approval | April 27, 2023
Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Apollo continues to invest in genomics technology and research for better patient care
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Fully equipped labs with 75-member team set-up and made operational in <100 days
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Subscribe To Our Newsletter & Stay Updated
